Because CompA and birinapant are structurally similar, but have different affinities to the IAPs, we evaluated expression of their targets cIAP1, cIAP2, and XIAP in ER+ and TNBC PDX tumors to understand the differential responsiveness of the breast cancer subtypes to Smac mimetics. Here, BIRC2 is linked to breast cancer.